ASH 2022 | The current role of immuno-oncology in AML and future outlooks
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the difficulties in developing effective immunotherapies for acute myeloid leukemia (AML). The immune system of AML patients, particularly in relapsed/refractory (R/R) cases, tends to be severely weakened prior to treatment, and variations between AML subtypes and clonal heterogeneity mean that treatments relying on patient immune function tend to lack efficacy. Dr Levis suggests that advances in allogeneic stem cell transplant (alloSCT) and NK-cell therapy may overcome these challenges and provide more options for patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
